Kieran F. Docherty

Jan 10, 2025 | onlinelibrary.wiley.com | Joanna Osmanska |Kieran F. Docherty |Colin Berry |Pardeep S. Jhund

Introduction Accurately estimating left ventricular (LV) filling pressure is crucial for guiding effective treatment decisions. Invasively measured pulmonary capillary wedge pressure (PCWP) is the gold standard method of indirectly estimating LV filling pressure. However, the routine invasive measurement of PCWP is limited by the availability of right heart catheterization and the risk of procedure-related complications.

Mar 28, 2024 | onlinelibrary.wiley.com | Kieran F. Docherty |John McMurray |Paul Kalra |John G.F. Cleland

Introduction Iron deficiency is common in patients with heart failure and is associated with anaemia and a poorer prognosis.

Mar 12, 2024 | heart.bmj.com | Daniel Doherty |Kieran F. Docherty

FootnotesTwitter @KieranfdochertyContributors DJD: conceived the review structure and contributed to the writing of the manuscript. RSG, KFD: provided expert appraisal and contributed to the writing of the manuscript. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Competing interests DJD has no declarations.

Jan 8, 2024 | heart.bmj.com | Daniel Doherty |Kieran F. Docherty |Roy S Gardner

Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dec 28, 2023 | jamanetwork.com | David D. Berg |Pardeep S. Jhund |Kieran F. Docherty |Sabina A. Murphy

Key PointsQuestion  When does the clinical benefit of dapagliflozin emerge in patients with heart failure with reduced ejection fraction, and what is the magnitude as a function of proximity to prior heart failure hospitalization? Findings  In this secondary analysis of a randomized clinical trial, dapagliflozin rapidly reduced the risk of cardiovascular death or worsening heart failure, with a sustained statistically significant benefit as soon as 28 days.